Reducing HAIs and SSIs Q Bio Technologies Ltd

Costs associated with HAI £1, Billion Per Year (England) 1 £183, Million per year (Scotland) Million Bed Days 1 1, Plowman R,. The socioeconomic burden of hospital acquired infection. Euro Surveill 2000;5(4): , Health Protection Scotland,. NHS SCOTLAND NATIONAL HAI PREVALENCE SURVEY July 2007

Incidence of C. difficile Trust category Large acute Medium acute Small acute Acute teaching Acute specialist C. difficile: no. of cases per 1,000 bed-days patients aged 65 years and over: Health Protection Agency,. Results of Mandatory Surveillance, January 2008

In the UK Approx. 9% UK patients acquire an infection in the hospital 2 Annual cost of HAI in the UK is approx £1 billion Approx. 5,000 UK patients die of hospital associated infections (HAI) annually 77% of post op deaths have a related SSI HAI are thought to be a contributing factor in the death of 15,000 UK patients 3 Population: 59.6 million 1 1) 2) Emmerson, AM,The National Survey of infection in hospitals- overview of results, J Hosp Infect, 1996; 32: ; 3)UK National Audit Report:

Breakdown of Hospital Acquired Infections England NHS Source: National Audit Office Feb 17. The Management and Control of Hospital Acquired Infection in Acute NHS Trusts in England. Note: 37,111 patients from 15 centres were studied over a 15 month period from May 1993 to July 1994 in two month study periods and a mean hospital acquired infection prevalence rate of 9% (range 2-29%) was calculated. Oth er BSI UTI SSI LRT Skin

Current Approaches Adopting best practice Anti-Microbial gel/ soaps Surgical scrub technique and solutions Impregnated medical devices Standard daily cleaning Specialist cleaning programs Treatment of areas after outbreaks (Bioquell)

Variations of Q Shield Q Bioshield 1 - limited initial knock down, persistent surface kill Q Bioshield 2 - has initial knock down and persistent surface kill Q Shield – kills faster and more than alcohol Hand sanitizer 50ml, 100ml, 600ml (foam) Skin sanitizer 100ml, 600ml (spray) Surface sanitizer 100ml, 500ml (spray)

The Q Shield System Provides a mechanism where every surface in a hospital plays an active role in reducing Healthcare Acquired Infections Provides microbe free hands for all staff, visitors and patients, all day and all night

What is unique about the Q shield system 1. Mode of action of 3 TSP molecule. 2. Pathogens killed, why no resistances. 3. Persistent nature of molecule. 4. How it is delivered/ used.

Additional information in-hospitals in-hospitals Papers, and research evidence (EN1500) Media YFH footfall increase and contracts won Numbers of users going up in the UK, Canada, Germany, China, Gulf states.

Summary of benefits Hard Wearing and durable Does not rub off or migrate (leaching) Controls or eliminates odours Does not promote resistance No arsenic, tin, heavy metals, or polychlorinated phenols More than 30 years of safe and effective use

Summary The kill potent of the Q Shield system is far greater than that of the current methods of sanitation. The real benefit of the 3TSP molecule is the persistent kill, this should be the number one reason for purchase for all varieties. It does 2 key things; 1 Significantly reduces the chances of re colonisation of the treated surfaces/ skin. 2 Reduces costs – direct and indirect.